Mission

Jorna Therapeutics is building the future of genome and transcriptome editing

<aside> 💡 At Jorna Therapeutics, we are developing the next generation tools for editing genomes and transcriptomes using cutting-edge synthetic biology, machine learning, and novel unified representations. We apply these tools to create therapeutics for genetic and degenerative diseases that are previously untreatable. We are also developing tools that can unlock previously unattainable potentials. So far, we have created novel tools that are unimaginable using traditional methods such as genome/metagenome mining, and they have produced profound impacts already (you can read an example story here on how we created a batch of novel Cas proteins using AI). With these steps as validation, we are now inviting you to join us to create an exciting future that is powered by the tools that you will design.

</aside>

Open Positions

Open positions

About Jorna Therapeutics

Jorna Therapeutics is a vibrant startup founded by scientists from the Broad Institute and Harvard working on AI-guided editor design and associated therapeutics. In the past, our work has helped our clients such as Sherlock Biosciences and the Gates Foundation tackle some unique challenges that they faced, which in turn formed the basis of our cutting-edge platform. Now we are taking on some of the most challenging problems in this field that could have a profound impact in how we treat genetic and degenerative diseases. We are inviting the most brilliant minds to join us on this exciting journey.

Jorna Therapeutics is a spin-off from Quantum Sky, a proud resident of LabCentral and the recipient of the Diamond Ticket by Astellas in 2024. We are currently located at 238 Main St, Cambridge, MA 0214.